[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2016 Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Country Volume and Sales Forecasts, Strategic Profiles of Leading Suppliers

November 2015 | 510 pages | ID: 2E3B4DDE73EEN
Venture Planning Group

US$ 6,000.00 US$ 7,500.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new report from VPGMarketResearch provides analysis of the global cancer diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers.

The report presents:
  • Estimated numbers of cancer testing laboratories, as well as test volume and sales forecasts for France, Germany, Italy, Japan, Spain, U.K. and U.S.
  • Marketing and technological assessment, as well as medical rationale and diagnostic prospects for major categories of circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.
  • Overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as listings of companies, universities and research centers developing or marketing new technologies, products, and applications.
  • Review of current instrumentation used for cancer diagnostic testing.
  • Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing.
  • Competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.
  • Profiles of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
Contains 510 pages and 31 tables
I. WORLDWIDE BUSINESS ENVIRONMENT

II. WORLDWIDE MARKET STRUCTURE

III. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
  ADA
  B-Protein
  PNP
  5'-Nucleotidase
27. Oncogenes
  Abl/abl-bcr
  AIB1
  BCL-2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP-17
  Erb-B
  HPC1
  N-myc
  P40
  P51
  P53
  PIK3CA
  PTI-1
  Ras
  Reg
  Sis
  Src
28. Polypeptide Growth Factors
  Basic Fibroblast Growth Factor
  Beta-TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
  Alpha-Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma-Interferon
  Interleukin-1 (IL-1)
  Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
  N-Acetylglucosamine
  Actin
  Alpha-Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD-F9
  BLCA-4
  Blood Group Antigens A,B,H
  CA
  CA 72-4/TAG-72
  CA
  CA-242
  CA-549
  CAM
  CAR-3
  Cathepsin-D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster-5/5A Antigen
  CTA
  CU18
  DR-70
  DU-PAN-2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1->3)-L-fucosyltransferase
  Gastrin-Releasing Peptide (GRP)
  GDCFP-15
  Glucagon
  Glycoamines
  H23
  Her-2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21-1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA-130
  NMP22
  OA-519
  Opiod Peptides
  P-glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki-67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA-1/SLX
  SN10
  Somatostatin
  TA-90
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen

IV. INSTRUMENTATION REVIEW: LEADING ANALYZERS MARKETED BY ABBOTT, BECKMAN COULTER/DANAHER, BINDING SITE, BIOMERIEUX, CAROLINA CHEMISTRIES, DIASORIN, HORIBA, INVERNESS/ALERE, J&J, OLYMPUS, ROCHE, SIEMENS, TOSOH, VITAL DIAGNOSTICS AND OTHER SUPPLIERS

V. CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
  a. Technological Principle
  b. Radioimmunoassay (RIA)
  c. Enzyme Immunoassays (EIA)
    Overview
    ELISA
    Immunofiltration
    Particle-Membrane Capture Immunoassay
    Enzyme Amplification
  d. Fluorescent Immunoassays
  e. Luminescence
    Chemiluminescence
    Bioluminescence
  f. Latex Agglutination
  g. Immunoprecipitation
  h. Affinity Chromatographu
  i. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
  a. Technology Overview
  b. Amplification Methods
    PCR
    DAP-PCR
    Immuno-PCR
    QC-PCR
    CAR
    DNA
    HPA
    LCR
    NASBA
    QBR
    SDA
    3 SR, and others
4. Chromosome Analysis
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
  a. CT
  b. MRI
  c. NMR
  d. PET
  e. Photonics Spectroscopy

VI. COMPETITIVE PROFILES

Abbott
AdnaGen
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Hologic/Gen-Probe
Guided Therapeutics
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo Fisher
Vermillion/Correlogic Systems
Wako Pure Chemicals
Wallac/PE
Zila

APPENDIXES: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING

Cancer Diagnostic Technologies and Applications

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Lymphokines in Cancer Diagnosis
Lymphokines Potential Applications
In Cancer Diagnosis
Immunohistochemical Stains Potential Lymphokines in Cancer Diagnosis
Worldwide, All Market Segments, Laboratories Performing Cancer Diagnostic Testing By Country
Worldwide, All Market Segments, Cancer Diagnostic Test Volume Forecasts By Country
Worldwide, All Market Segments, Cancer Diagnostics Sales Forecasts By Country


More Publications